Beyond the Silos: A Unified Approach to Cardiometabolic and Kidney Care

PA Le dives into therapy options for each stage of CKM, emphasizing how lifestyle changes and pharmacologic treatments can work together. He reviews how to optimize care for comorbidities such as obesity, diabetes, hypertension, CKD, and heart failure using evidence-based medications like SGLT2 inhibitors, GLP-1 receptor agonists and nsMRAs. The video emphasizes that many of these therapies address multiple CKM-related risks simultaneously. Providers will leave with a clear understanding of how to approach CKM treatment holistically, moving beyond siloed care.

Key Takeaways:

CV, kidney, and metabolic conditions are all related; some of the same pathophysiological mechanisms are behind them.
Preventing HF requires us to consider metabolic health, blood pressure control, kidney protection, and ASCVD treatment.
At each stage, we have additional opportunities to intervene with medication.

Previous Video Next Video

Speaker

Click on the photo below to learn more about the speaker.

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

References and Additional Resources:

Abreu AP de, Drager LF, Almeida MQ, Bortolotto LA, Lopes HF. Cardiovascular-kidney-metabolic Syndrome: a current and urgent concept. J Bras Nefrol. 2025;47(2):e20240277. doi:10.1590/2175-8239-JBN-2024-0277en

American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: Standards of care in diabetes-2025. Diabetes Care. 2025;48(1 Suppl 1):S239-S251. doi:10.2337/dc25-S011

Khan SS, Breathett K, Braun LT, et al. Risk-based primary prevention of Heart Failure: A scientific statement from the American Heart Association. Circulation. 2025;151(20):e1006-e1026. doi:10.1161/CIR.0000000000001307

Kidney failure risk factor: Urine albumin-creatinine ratio (uACR). National Kidney Foundation. Accessed July 29, 2025. https://www.kidney.org/kidney-failure-risk-factor-urine-albumin-creatinine-ratio-uacr

Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023;22(1):195. doi:10.1186/s12933-023-01937-x

Naaman SC, Bakris GL. Diabetic nephropathy: Update on pillars of therapy slowing progression. Diabetes Care. 2023;46(9):1574-1586. doi:10.2337/dci23-0030

Supported by

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert

Viet is an Associate Professor of Research and Preventive Cardiology PA at Intermountain Medical Center and co-directs the Preventive Cardiology Clinic. He has a bachelor’s in exercise science/athletic training, trained as a physician assistant at the University of Utah School of Medicine, and obtained his doctorate in Health Professions Education. He is Principal/Sub-Investigator on clinical trials and has authored/co-authored over 80 abstracts and 50 publications. He is past president of the Academy of PAs in Cardiology, past co-chair of the American College of Cardiology PA Work Group, and serves as the President of the Utah Academy of PAs.